Left untreated, multiple sclerosis causes a slow but measurable accumulation of disability over years and decades. In a large natural history study of over 1,800 patients, it took a median of about 8 years to reach the point of limited walking ability, 20 years to need a walking aid, and 30 years to need a wheelchair. Those timelines vary enormously depending on the type of MS and individual factors, but the overall direction without treatment is toward increasing neurological damage that the body cannot repair.
How Disability Builds Over Time
MS progression is often described in terms of disability milestones. The most studied natural history data, from a cohort of 1,844 patients in Lyon, France, maps out these milestones clearly. For patients who started with the most common form, relapsing-remitting MS (RRMS), it took a median of about 11 years to develop noticeable gait problems, 23 years to require a cane or similar aid for walking, and 33 years to largely need a wheelchair.
For the roughly 15% of patients who start with a progressive form of MS from the outset, the timeline compresses dramatically. These patients reached the need for a walking aid in about 7 years and a wheelchair in about 13 years. The gap between these two groups highlights how variable the disease can be, and why “untreated MS” doesn’t have a single outcome.
The Shift to Progressive Disease
One of the most significant things that happens without treatment is the transition from relapsing-remitting MS to secondary progressive MS (SPMS). In RRMS, symptoms flare up during relapses and then partially or fully recover. In SPMS, disability accumulates steadily, with or without relapses, and recovery between episodes becomes less and less complete.
In natural history studies of untreated patients, about 50% progressed to SPMS within 10 to 20 years of disease onset. Once this transition happens, the disease becomes harder to manage and currently available treatments are less effective. This is one of the strongest arguments for early treatment: it can delay or potentially prevent this shift.
Brain Shrinkage Accelerates
Everyone loses a small amount of brain volume with normal aging. In untreated MS, that loss runs at roughly 0.5% to 1.35% per year, significantly faster than what’s expected in healthy adults. This accelerated brain shrinkage starts early, sometimes even before a formal diagnosis, and it’s the strongest predictor of future physical and cognitive disability.
What makes this particularly concerning is that brain volume loss happens silently. You won’t feel your brain shrinking. By the time symptoms become obvious, a significant amount of tissue has already been lost. This is the biological basis for the concept of “brain health” in MS care: preserving brain volume early, when there’s the most to protect.
Cognitive Decline
MS isn’t just a disease of walking and balance. Between 40% and 65% of people with MS experience some degree of cognitive impairment. Memory retrieval is the most commonly affected ability. In one study of 426 patients, 66% had difficulty recalling previously learned information, while only 14% had trouble forming new memories in the first place. The brain “records” information fine but struggles to pull it back up on demand.
Processing speed, attention, and the ability to juggle multiple tasks also decline over time. These cognitive changes can affect work performance, relationships, and daily decision-making years before physical disability becomes severe. Without treatment to slow new damage, these deficits tend to worsen alongside the physical symptoms.
Bladder and Bowel Problems
Nerve damage from MS frequently disrupts the signals that control bladder and bowel function. These symptoms are common and tend to worsen with disease duration. In a group of patients with an average disease duration of about 18 years, nearly half experienced constipation and about a third experienced fecal incontinence. Both problems were significantly associated with how long someone had lived with MS, even after accounting for age.
These symptoms often go underreported because they’re embarrassing, but they have an outsized effect on quality of life. They can restrict social activities, disrupt sleep, and create anxiety about leaving home. Without treatment to slow the nerve damage driving these problems, they tend to become more frequent and harder to manage over time.
What About Vision?
Optic neuritis, an inflammation of the nerve connecting the eye to the brain, is one of the most recognizable early symptoms of MS. The good news here is more reassuring than many people expect. Visual function typically returns to near-normal levels over weeks to months, whether or not the episode is specifically treated. Only about 3% of patients have significantly impaired vision after five years.
That said, repeated episodes of optic neuritis can cause cumulative damage. Each bout carries a small risk of incomplete recovery, and over decades of untreated disease with recurring inflammation, that risk adds up. The individual episodes are usually not devastating, but the pattern of repeated injury without disease control is what creates lasting problems.
Some People Do Well Without Treatment
Not everyone with untreated MS follows a trajectory of worsening disability. The concept of “benign MS” describes patients who remain minimally affected for years. Between 30% and 80% of RRMS patients in various studies had minimal disability after 10 or more years. In one well-studied cohort from British Columbia, about half of patients classified as benign at the 10-year mark were still doing well after 20 years. Among those with the very lowest disability scores at 10 years, two-thirds maintained that status a decade later.
The challenge is that there’s no reliable way to predict at diagnosis who will follow a benign course. And “benign” by physical measures doesn’t always mean benign in practice. Many of these patients still experience fatigue, cognitive difficulties, or pain that don’t show up on standard disability scales. Betting on a benign outcome is a gamble with no way to know the odds in advance.
Life Expectancy
Despite the significant disability MS can cause, most people with the disease have a normal or near-normal life expectancy. MS is not typically a fatal condition. The concern with leaving it untreated isn’t primarily about shortening your life. It’s about the quality of the decades you’ll live. The difference between walking independently at 50 and needing a wheelchair at 50 is enormous in practical terms, even if both scenarios involve a normal lifespan.
The real cost of untreated MS is measured in lost mobility, lost cognitive sharpness, lost independence, and the accumulation of symptoms that chip away at daily life year by year. Modern disease-modifying therapies don’t cure MS, but they can meaningfully slow that accumulation, particularly when started early before significant damage has occurred.